MTL Cannabis Past Earnings Performance
Past criteria checks 3/6
MTL Cannabis has been growing earnings at an average annual rate of 29.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 132% per year. MTL Cannabis's return on equity is 28.1%, and it has net margins of 6.6%.
Key information
29.9%
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 132.0% |
Return on equity | 28.1% |
Net Margin | 6.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How MTL Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 73 | 5 | 22 | 0 |
31 Mar 24 | 65 | 2 | 18 | 0 |
31 Dec 23 | 59 | 1 | 15 | 0 |
30 Sep 23 | 47 | 0 | 12 | 0 |
30 Jun 23 | 32 | -3 | 9 | 0 |
31 Mar 23 | 25 | -2 | 8 | 0 |
31 Dec 22 | 22 | -5 | 10 | 0 |
31 Mar 22 | 22 | 2 | 8 | 0 |
31 Mar 21 | 13 | 1 | 3 | 0 |
Quality Earnings: J4E has high quality earnings.
Growing Profit Margin: J4E became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: J4E's earnings have grown significantly by 29.9% per year over the past 5 years.
Accelerating Growth: J4E has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: J4E has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: Whilst J4E's Return on Equity (28.06%) is high, this metric is skewed due to their high level of debt.